文献速递淋巴瘤

衰弱与非衰弱弥漫大B细胞淋巴瘤患者的医疗资源利用与费用对比

Health care utilization and costs for frail vs nonfrail patients with diffuse large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2024-01-01

该回顾性队列研究基于加拿大安大略省人群数据,纳入2006至2017年间接受一线根治性化学免疫治疗的5527例≥66岁弥漫大B细胞淋巴瘤患者,其中49%为衰弱。按5个治疗阶段分析,衰弱患者在多数阶段的医疗资源利用率和费用均高于非衰弱患者,但临终阶段除外。

要点

  • 5527例老年DLBCL患者中,2699例(49%)被判定为衰弱。
  • 各阶段每30天中位费用衰弱组均高于非衰弱组,差异均有统计学意义。
  • 临终阶段84%(2569例)需住院,27%(684例)需入住重症监护室。

核心结论

  • 衰弱患者在各治疗阶段的急诊就诊率和住院率更高、费用更高,但临终阶段除外。
  • 未来工作可评估某些住院是否可预防,尤其对衰弱患者。

研究设计与样本

  • 回顾性队列研究,使用加拿大安大略省基于人群的数据。
  • 纳入2006至2017年间接受一线根治性化学免疫治疗的≥66岁DLBCL患者,共5527例(中位年龄75岁;48%女性)。
  • 衰弱采用基于累积缺陷的衰弱指数定义,2699例(49%)被归类为衰弱。

主要发现

  • 每30天中位费用(衰弱组 vs 非衰弱组):治疗前90天为5683加元 vs 2586加元;治疗早期(0至+90天)为13090加元 vs 11256加元;治疗后期(+91至+180天)为5734加元 vs 4883加元;随访期(+181至死亡前181天)为1138加元 vs 686加元;临终期(死亡前最后180天)为11413加元 vs 9089加元;所有阶段差异均有统计学意义。
  • 多变量模型中,衰弱患者在除临终阶段外的所有阶段急诊就诊率和住院率更高、费用更高。
  • 临终阶段,2569例(84%)需住院,684例(27%)需入住重症监护室。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Half of older patients with diffuse large B-cell lymphoma (DLBCL) receiving curative-intent treatment are frail. Understanding the differences in health care utilization including costs between frail and nonfrail patients can inform appropriate models of care. A retrospective cohort study was conducted using population-based data in Ontario, Canada. Patients aged ≥66 years with DLBCL who received frontline curative-intent chemoimmunotherapy between 2006 and 2017 were included. Frailty was defined using a cumulative deficit-based frailty index. Health care utilization and costs were grouped into 5 phases: (1) 90 days preceding first treatment; (2) early treatment (0 to +90 days after starting treatment); (3) late treatment (+91 to +180 days); (4) follow-up (+181 to -181 days before death); and (5) end of life (last 180 days before death). Costs were standardized to 30-day intervals (2019 Canadian dollars). A total of 5527 patients were included (median age, 75 years; 48% female). A total of 2699 patients (49%) were classified as frail. The median costs for frail vs nonfrail patients per 30 days based on phase of care were (1) $5683 vs $2586 ; (2) $13 090 vs $11 256; (3) $5734 vs $4883; (4) $1138 vs $686; and (5) $11 413 vs $9089; statistically significant in all phases. In multivariable modeling, frail patients had higher rates of emergency department visits and hospitalizations and increased costs than nonfrail patients through all phases except end-of-life phase. During end-of-life phase, a substantial portion of patients (n = 2569 [84%]) required admission to hospital; 684 (27%) required intensive care unit admission. Future work could assess whether certain hospitalizations are preventable, particularly for patients identified as frail.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Vijenthira A, Calzavara A, Nagamuthu C, et al. Health care utilization and costs for frail vs nonfrail patients with diffuse large B-cell lymphoma. Blood Adv. 2024. PMID: 39024541. doi:10.1182/bloodadvances.2024013158

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。